610.12 CBER PROPOSED STERILITY TESTS

PART 610.12 — CBER GENERAL BIOLOGICAL PRODUCTS STANDARDS PROPOSED
 

Enclosed is the summary of the proposed requirements for the revised CBER 610.12 Sterility Test. For additional information, please see below for a summary or visit the enclosed web site for the full release http://www.gpo.gov/fdsys/pkg/FR-2011-06-21/pdf/2011-15346.pdf

The authority citation for 21 CFR part 610 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360, 360c, 360d, 360h, 360i, 371, 372, 374, 381; 42 U.S.C. 216, 262, 263, 263a, 264.

Section 610.12 is revised to read as follows:

§ 610.12 Sterility.

(a) The test.

Except as provided in paragraph (h) of this section, manufacturers of biological products must perform sterility testing of each lot of each biological product’s final container material or other material, as appropriate and as approved in the biologics license application or supplement for that product.

(b) Test requirements.

(1) The sterility test must be appropriate to the material being tested such that the material does not interfere with or otherwise hinder the test.

(2) The sterility test must be validated to demonstrate that the test is capable of reliably and consistently detecting the presence of viable contaminating microorganisms.

(3) The sterility test and test components must be verified to demonstrate that the test method can consistently detect the presence of viable contaminating microorganisms.

MEDIA FILLS FOR VALIDATION OF ASEPTIC PREPARATIONS FOR POSITRON EMISSION TOMOGRAPHY (PET) DRUGS

CDER RELEASES A NEW PET DRAFT GUIDANCE

CDER has released as a DRAFT the following Guidance for Industry, “Media Fills for Validation of Aseptic Preparation for Positron Emission Tomography (PET) Drugs.  The Comment period will be 90 days.

Please visit: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273766.pdf to obtain this DRAFT document.

Novatek’s NOVA-EM

The Environmental Monitoring Data Management & Trending System Software – The Industry Standard It seems like just yesterday, when the Pharmaceutical Microbiology Forum Newsletter – March 2004, Vol. 11 (1) was published. One of the hot topics at the time was Environmental Monitoring (EM) and the question of the day was: How many people are…

Novatek International contributes again in the latest PDA publication, “Environmental Monitoring” Volume 6

Novatek International is very proud to once again announce that Ms. Susan Cleary, Associate Directors of R&D and Mr. Parsa Famili, President and CEO at Novatek International have contributed to the recent PDA publication: Environmental Monitoring, Volume 6, edited by Jeanne Moldenhauer, chapter 16 “Automation of Environmental Monitoring; Achieving Efficiency and Control”, 2012. This series is an edited volume with contributions from world experts. It provides readers with unique contributions related to current research and the future of Environmental Monitoring. Practitioners and researchers focused on microbiology, research and development, quality and environmental monitoring will find this book a valuable daily reference. Ms. Cleary and Mr. Famili have previously published number of chapters and articles, notably Environmental Monitoring, Volume 2, edited by Jeanne Moldenhauer, chapter 25 “Acquisition and Implementation of an Environmental Monitoring Program”. We encourage you to read Novatek International’s latest contribution in this highly informative PDA publication.

Xplore and Novatek Partner to Provide Rugged Tablet Solution Specialized for the Pharmaceutical & Biopharmaceutical Industry

Novatek International’s commitment to providing regulatory compliant software solutions to the pharmaceutical and biotech industries takes another leap forward with their newest addition to their Nova-EM Environmental Monitoring Management process, Nova-EM Mobile. In collaboration with Xplore Technologies’  iX104c5 DMCR (Dual-Mode Clean Room Tablet ) , the Nova-EM Mobile solution offers an effective real-time data collection…

Risk Based Environmental Monitoring & Efficiencies Gained With Use of an Automated System – An Industry Roundtable Discussion

The Southern California Discussion Group of the ASQ Biomedical Division Presents: Risk Based Environmental Monitoring (EM): How to use risk to ensure your EM Program is value added & efficient An Industry Roundtable Discussion Non-viable air, viable air, and surface monitoring of controlled environments is not a new concept and has been a regulatory requirement…